<p>Mice that were administered AF, infected with 1LD<sub>50</sub> of PR/8 virus or immunized with 1,000 pfu of GP42-GFP, or 1,000 pfu GP42-H1 (i.n.) were challenged (seven weeks post-immunization) with 5LD<sub>50</sub> of PR/8 virus (i.n.) A) Body weight was recorded over 14 days and the percent of the body weight at the time of challenge is shown. B) Animals were monitored for 14 days post challenge and morbidity is recorded. Depicted are the percentages of mice that survived the virus challenge.</p
<p>Mice (n = 10/groups) were immunized subcutaneously on day 0 and 28. All groups were challenged in...
<p>Groups of mice (n = 4) were immunized 1 or 2 times, 4 weeks apart, with IDLV-NP via either the i....
<p>Survival rates (A) and bodyweight changes (B) after challenge with the viruses. BALB/c mice were ...
<p>Survival rates of immunized mice were monitored for 10 days after i.n. infection with mouse adapt...
<p>A. Body weight loss in vaccinated/challenged C57/B6 mice. Mice were vaccinated with Pol1, Pol2, A...
<p>A–B: Protection against A/California/04/2009 virus challenge. Mice intramuscularly immunized with...
<p>BALB/c mice were treated with PR8-specific IgY (anti PR8 IgY) - as described in <a href="http://w...
<p>BALB/c mice were immunized intranasally or sublingually with 1×10<sup>7</sup> PFU or 1×10<sup>8</...
<p>Mice were immunized thrice with gB, gH, gL, gO, gH/gL, gH/gO, gL/gO and gH/gL/gO pDNAs at a dosag...
<p>Immunized mice were challenged with a lethal dose (40 LD<sub>50</sub>) of A/PR8 (<b>A</b> and <b>...
<p>At 18 days following the last immunization, all mice in study group B were intranasally challenge...
<p>At week 5, mice vaccinated with clade 2-dervied vaccines were challenged intranasally with a leth...
<p>Mice (n = 6/groups) were immunized subcutaneously on day 0 and 28. All groups were challenged int...
<p>BALB/c mice (n = 4) were infected with a lethal dose (500 pfu in 50 µl) of PR8 virus via the TRT ...
<p>BALB/c mice (n = 5) were treated with 1 mg of the Ab preparations or PBS in 50 µl i.n. under pent...
<p>Mice (n = 10/groups) were immunized subcutaneously on day 0 and 28. All groups were challenged in...
<p>Groups of mice (n = 4) were immunized 1 or 2 times, 4 weeks apart, with IDLV-NP via either the i....
<p>Survival rates (A) and bodyweight changes (B) after challenge with the viruses. BALB/c mice were ...
<p>Survival rates of immunized mice were monitored for 10 days after i.n. infection with mouse adapt...
<p>A. Body weight loss in vaccinated/challenged C57/B6 mice. Mice were vaccinated with Pol1, Pol2, A...
<p>A–B: Protection against A/California/04/2009 virus challenge. Mice intramuscularly immunized with...
<p>BALB/c mice were treated with PR8-specific IgY (anti PR8 IgY) - as described in <a href="http://w...
<p>BALB/c mice were immunized intranasally or sublingually with 1×10<sup>7</sup> PFU or 1×10<sup>8</...
<p>Mice were immunized thrice with gB, gH, gL, gO, gH/gL, gH/gO, gL/gO and gH/gL/gO pDNAs at a dosag...
<p>Immunized mice were challenged with a lethal dose (40 LD<sub>50</sub>) of A/PR8 (<b>A</b> and <b>...
<p>At 18 days following the last immunization, all mice in study group B were intranasally challenge...
<p>At week 5, mice vaccinated with clade 2-dervied vaccines were challenged intranasally with a leth...
<p>Mice (n = 6/groups) were immunized subcutaneously on day 0 and 28. All groups were challenged int...
<p>BALB/c mice (n = 4) were infected with a lethal dose (500 pfu in 50 µl) of PR8 virus via the TRT ...
<p>BALB/c mice (n = 5) were treated with 1 mg of the Ab preparations or PBS in 50 µl i.n. under pent...
<p>Mice (n = 10/groups) were immunized subcutaneously on day 0 and 28. All groups were challenged in...
<p>Groups of mice (n = 4) were immunized 1 or 2 times, 4 weeks apart, with IDLV-NP via either the i....
<p>Survival rates (A) and bodyweight changes (B) after challenge with the viruses. BALB/c mice were ...